Acceptability of liquid human growth hormone (hGH) [Norditropin SimpleXx®] in adults and children with GH deficiency and children with chronic renal disease

Clinical Drug Investigation

Volumn 22, Issue 9, 2002, Pages 633-638

  Drent, M L ^a   Jakobsdottir, S ^a   Van Wijk, J A E ^a   Oostdijk, W ^b   Wit, J M ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN GROWTH HORMONE; NORDITROPIN SIMPLEXX;

ADOLESCENT; ADULT; ARTICLE; ASTHENIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MONITORING; DRUG TOLERABILITY; EDEMA; FEMALE; GROWTH HORMONE DEFICIENCY; HORMONAL THERAPY; HUMAN; INJECTION PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NETHERLANDS; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUESTIONNAIRE; SCHOOL CHILD; SELF INJECTION; TREATMENT OUTCOME;

EID: 0036042720     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200222090-00008     Document Type: Article

References (9)

1. Multicentre survey on compliance with growth hormone therapy: What can be improved?
2. Improvement of patient convenience in treatment with growth hormone
3. Pain assessment of subcutaneous injections
4. Automatic needle insertion diminishes pain during growth hormone injection
5. What makes insulin injections painful?
6. Compliance with growth hormone treatment: Are they getting it?
7. The clinical usefulness of liquid human growth hormone (hGH) (Nordtropin® SimpleXx™) in the treatment of GH deficiency
8. Norditropin® SimpleXx™: A liquid human growth hormone formulation, a pen system and an auto-insertion device
9. An open-label acceptability study of Norditropin SimpleXx: A new liquid growth hormone formulation